NCT00877448View on ClinicalTrials.gov

A Double-Dose Safety Study of An Influenza Vaccine (Multimeric-001)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

June 30, 2009

Primary Completion Date

October 31, 2009

Study Completion Date

November 30, 2009

Conditions
Healthy
Interventions
BIOLOGICAL

Adjuvanted Multimeric-001 250 Mcg

BIOLOGICAL

Multimeric-001 250 Mcg

BIOLOGICAL

Phosphate Buffered saline

BIOLOGICAL

Adjuvanted PBS

BIOLOGICAL

Adjuvanted Multimeric-001 500 Mcg

BIOLOGICAL

Multimeric-001 500 Mcg

BIOLOGICAL

Multimeric-001 125 Mcg

Trial Locations (1)

Unknown

Tasmc Crc, Tel Aviv

Sponsors
All Listed Sponsors
lead

BiondVax Pharmaceuticals ltd.

INDUSTRY